Home/ Stocks/ GANX

Gain Therapeutics, Inc. Common Stock

GANX XNAS

$1.82 +0.04 (+2.25%) ▲ 15-min delayed

Open

$1.80

High

$1.85

Low

$1.78

Volume

342.9K

Market Cap

$75.92M

About Gain Therapeutics, Inc. Common Stock

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 21 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-5,608,732	$-0.13
FY 2025	$0	$-20,161,099	$-0.61
Q3 2025	$0	$-5,284,373	$-0.15
Q2 2025	$0	$-5,809,087	$-0.19

Related Market News

No specific coverage for GANX yet. Check out our latest market news or earnings calendar.

Get GANX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Gain Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.